Healthcare
Live Price
Offline$84.71
+3.15% today
1Y Change
+31.45%
Window
Jun 26, 2025 → Jun 15, 2026
Coverage: 244 bars · Jun 26, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Globus Medical, Inc. (GMED) is a Healthcare stock with a market cap of $12.17B and listed on NYSE. The stock last traded around $84.71 and up 31.5% across the available one-year price window (Jun 26, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +16.7%, EPS growth of +423.7%, a dividend yield of 0.0%. What stands out right now is revenue +16.7%, EPS +423.7%, free cash flow +45.3% with operating margin 16.3% and ROIC 8.8%. Valuation sits in the middle of the pack at P/E 22.6 and price/sales 4.1. Stock Foundry combines GMED price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GMED
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GMED Max Drawdown
-21.95%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for GMED and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$958.1M
-6.3% YoY
FY Net Income
$149.2M
-21.5% YoY
Free Cash Flow
$219.4M
+110.1% YoY
Revenue Growth
+16.7%
EPS Growth
+423.7%
Gross Margin
67.4%
Net Margin
18.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.9B | 2.5B | 1.6B | 1.0B | 958M |
| Gross Profit | 2.0B | 1.5B | 1.0B | 759M | 719M |
| Operating Income | 480M | 166M | 133M | 228M | 172M |
| EBITDA | 730M | 474M | 347M | 305M | 265M |
| Net Income | 538M | 103M | 123M | 190M | 149M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 526M | 784M | 467M | 150M | 193M |
| Total Assets | 5.3B | 5.3B | 5.1B | 2.1B | 2.0B |
| Total Liabilities | 730M | 1.1B | 1.1B | 230M | 216M |
| Shareholder Equity | 4.6B | 4.2B | 4.0B | 1.8B | 1.7B |
| Total Debt | 119M | 537M | 520M | 6M | 0 |
| Net Debt | -408M | -247M | 53M | -144M | -193M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
276M
+54.8% YoY
Capital Expenditures
57M
+23.2% YoY
Free Cash Flow
219M
+110.1% YoY
Key ratios
Gross Margin
67.4%
Operating Margin
16.3%
Net Margin
18.3%
ROE
12.4%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.